These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3558984)

  • 81. [Acute and chronic effects of a new oral inotropic agent, ibopamine hydrochloride, on hemodynamic and metabolic responses to ergometer exercise in patients with severe congestive heart failure].
    Morimoto Y; Kasai A; Nagano K; Umino M; Kakuta Y; Iwata J; Hamada M; Konishi T; Nakano T
    Kokyu To Junkan; 1989 Jul; 37(7):773-8. PubMed ID: 2799097
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with congestive heart failure.
    Tisdale JE; Gheorghiade M
    Am J Cardiol; 1992 Jun; 69(18):34G-47G. PubMed ID: 1626491
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effect of vesnarinone on cardiac function in patients with severe congestive heart failure.
    Scherrer-Crosbie M; Cocca-Spofford D; DiSalvo TG; Semigran MJ; Dec GW; Picard MH
    Am Heart J; 1998 Nov; 136(5):769-77. PubMed ID: 9812070
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Nifedipine in congestive heart failure: effects on resting and exercise hemodynamics and regional blood flow.
    Leier CV; Patrick TJ; Hermiller J; Pacht KD; Huss P; Magorien RD; Unverferth DV
    Am Heart J; 1984 Dec; 108(6):1461-8. PubMed ID: 6507242
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effect of a single oral dose of milrinone on left ventricular diastolic performance in the failing human heart.
    Piscione F; Jaski BE; Wenting GJ; Serruys PW
    J Am Coll Cardiol; 1987 Dec; 10(6):1294-302. PubMed ID: 3680800
    [TBL] [Abstract][Full Text] [Related]  

  • 86. New concepts and drugs in the treatment of congestive heart failure.
    Friedman WF; George BL
    Pediatr Clin North Am; 1984 Dec; 31(6):1197-227. PubMed ID: 6390312
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Haemodynamic effects of intravenous and oral alifedrine in patients with cardiac failure.
    Wan SK; Hoff W; Evans TR
    Curr Med Res Opin; 1988; 11(4):242-53. PubMed ID: 3215041
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Management of severe chronic CHF with oral pirbuterol.
    Awan NA; Needham K; Evenson MK; Mason DT
    Acta Med Scand Suppl; 1981; 652():155-62. PubMed ID: 6949462
    [No Abstract]   [Full Text] [Related]  

  • 89. Clinical overview of the novel inotropic agent toborinone.
    MacGowan GA
    Expert Opin Investig Drugs; 2000 May; 9(5):1109-17. PubMed ID: 11060731
    [TBL] [Abstract][Full Text] [Related]  

  • 90. [Therapy of acute heart failure, medicamentous strategy].
    Kleber FX
    Z Kardiol; 1999 Jun; 88(6):394-9. PubMed ID: 10441809
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Are inotropic agents contraindicated in congestive heart failure?
    Katz AM
    Cardiovasc Drugs Ther; 1989 Jan; 2(6):747-50. PubMed ID: 2488087
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Quinolinone derivatives in the management of congestive heart failure.
    Feldman AM; Strobeck JE
    Coron Artery Dis; 1994 Feb; 5(2):107-11. PubMed ID: 8180742
    [No Abstract]   [Full Text] [Related]  

  • 93. Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells.
    Uchida D; Onoue T; Begum NM; Kuribayashi N; Tomizuka Y; Tamatani T; Nagai H; Miyamoto Y
    Mol Cancer; 2009 Aug; 8():62. PubMed ID: 19671192
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell.
    Kawamata H; Nakashiro K; Uchida D; Hino S; Omotehara F; Yoshida H; Sato M
    Br J Cancer; 1998; 77(1):71-8. PubMed ID: 9459148
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Beyond ejection fraction.
    Marmor A; Jain D; Zaret B
    J Nucl Cardiol; 1994; 1(5 Pt 1):477-86. PubMed ID: 9420731
    [No Abstract]   [Full Text] [Related]  

  • 96. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
    Matsui S; Matsumori A; Matoba Y; Uchida A; Sasayama S
    J Clin Invest; 1994 Sep; 94(3):1212-7. PubMed ID: 8083362
    [TBL] [Abstract][Full Text] [Related]  

  • 97. OPC-8212 in the treatment of congestive heart failure: results of a pilot study.
    Kubo SH; Rector TS; Strobeck JE; Cohn JN
    Cardiovasc Drugs Ther; 1988 Dec; 2(5):653-60. PubMed ID: 3154640
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.
    von der Leyen H
    Klin Wochenschr; 1989 Jun; 67(12):605-15. PubMed ID: 2671473
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group.
    Cardiovasc Drugs Ther; 1990 Apr; 4(2):419-25. PubMed ID: 2285626
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of OPC-8490 on the membrane potentials and membrane currents of single guinea-pig myocytes.
    Momose Y; Sasayama S
    Cardiovasc Drugs Ther; 1990 Jun; 4(3):713-7. PubMed ID: 1963791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.